PMSC 13
Alternative Names: PMSC-13Latest Information Update: 03 Oct 2024
At a glance
- Originator Immorta Bio
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 11 Sep 2024 Early research in Unspecified in USA (Parenteral) prior to September 2024 (Immorta Bio website, September 2024)